• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Targeting ESR1 Mutations Early May Improve Outcomes in Breast Cancer

by MM360 Staff | Jun 3, 2025 | Uncategorized

Source: CureToday articles Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer. Read More

FDA Approves Nubeqa in Metastatic Castration-Sensitive Prostate Cancer

by MM360 Staff | Jun 3, 2025 | Uncategorized

Source: CureToday articles The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic progression-free survival data. Read More

COCOON Dermatologic Regimen Improves QOL in EGFR+ Lung Cancer

by MM360 Staff | Jun 3, 2025 | Uncategorized

Source: CureToday articles COCOON dermatologic management lessened skin side effects and improved quality of life versus standard care for patients with lung cancer. Read More

You Are Not a Statistic: Facing Cancer With Hope, Not Numbers

by MM360 Staff | Jun 3, 2025 | Uncategorized

Source: CureToday articles I’m here to prove that powerful phrase; after nearly 16 years living with incurable cancer, I know there’s more to my story than the statistics. Read More

Patritumab Deruxtecan Does Not Improve Survival Outcomes vs Chemo in EGFR+ NSCLC

by MM360 Staff | Jun 3, 2025 | Uncategorized

Source: CureToday articles Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ advanced/metastatic NSCLC. Read More

COCOON Regimen Eases Dermatologic Side Effects After Treatment in EGFR+ NSCLC

by MM360 Staff | Jun 3, 2025 | Uncategorized

Source: CureToday articles The COCOON dermatologic management regimen reduced the quality-of-life impact of Rybrevant/Lazcluze vs SOC treatment in patients with EGFR-mutated NSCLC. Read More
« Older Entries
Next Entries »

Recent Content

  • A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)
  • High Response Rates With Talquetamab Plus Teclistamab in Triple-Class Refractory Multiple Myeloma
  • Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials
  • Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
  • You Are Not Alone While Building a Support Team During Cancer Care
  • Single Infusion of Cilta-Cel Yields 5-Year Progression-Free Survival in Multiple Myeloma
  • When Treatment Ends, Support Shouldn’t Stop in Cancer Care
  • Sequencing Strategies and the Role of Combination Therapy
  • Comparative Efficacy and Safety of Daratumumab-Integrated Quadruple Therapy Versus Triple Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
  • Being in the Present Moment With Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT